Renexxion
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact

Functional Dyspepsia

Functional dyspepsia is characterized by a number of symptoms associated with upper intestinal discomfort. In 2006, a specialist panel of clinicians issued a report entitled Rome III recommending that certain of these symptoms, including mid-to-upper abdominal discomfort characterized by postprandial fullness, early satiety or upper abdominal bloating, be classified as postprandial distress syndrome, or PDS. These symptoms are believed to be associated with deficiencies in motility of the upper gastrointestinal tract. Naronapride is being developed for the treatment of PDS. No currently marketed therapy is considered to be an optimal treatment for this condition. It is estimated that between 35 and 44 million people suffer from functional dyspepsia in the United States.
Privacy Policy & Terms of Use 
​Copyright Renexxion 2016. All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact